71066-28-9

Usage

Uses

Used in Pharmaceutical Applications:
AMBP is used as a chelating agent for metal ions in the pharmaceutical industry, particularly for the treatment of diseases such as osteoporosis and bone metastases. Its strong metal-binding properties make it a promising candidate for these applications, as it can help regulate the body's mineralization processes and prevent the loss of bone density.
Used in Environmental Management:
In the field of environmental management, AMBP is utilized for its ability to remove toxic heavy metals from wastewater and other environmental pollutants. Its strong metal-binding properties allow it to effectively sequester and neutralize harmful metals, reducing their impact on ecosystems and human health.
Used in Industrial Processes:
AMBP is also employed in various industrial processes, where its metal-binding capabilities are harnessed to improve the efficiency and performance of certain applications. For instance, it can be used to prevent the formation of calcium phosphate, which can lead to the development of kidney stones, or to enhance the stability and performance of certain chemical reactions.
Overall, [(3-methylbutyl)amino]methanediylbis(phosphonic acid), or AMBP, is a versatile compound with a broad spectrum of applications across different industries, making it a valuable asset in the development of new technologies and treatments.

Relevant academic research and scientific papers

Effects of Bisphosphonates on the Growth of Entamoeba histolytica and Plasmodium Species in Vitro and in Vivo

The effects of a series of 102 bisphosphonates on the inhibition of growth of Entamoeba histolytica and Plasmodium falciparum in vitro have been determined, and selected compounds were further investigated for their in vivo activity. Forty-seven compounds tested were active (IC50 50 ～ 4-9 μM) were nitrogen-containing bisphosphonates with relatively large aromatic side chains. Simple n-alkyl-1-hydroxy-1,1-bisphosphonates, known inhibitors of the enzyme farnesylpyrophosphate (FPP) synthase, were also active, with optimal activity being found with C9-C10 side chains. However, numerous other nitrogen-containing bisphosphonates known to be potent FPP synthase inhibitors, such as risedronate or pamidronate, had little or no activity. Several pyridine-derived bisphosphonates were quite active (IC50 ～ 10-20 μM), and this activity was shown to correlate with the basicity of the aromatic group, with activity decreasing with increasing pKa values. The activities of all compounds were tested versus a human nasopharyngeal carcinoma (KB) cell line to enable an estimate of the therapeutic index (TI). Five bisphosphonates were selected and then screened for their ability to delay the development of amebic liver abscess formation in an E. histolytica infected hamster model. Two compounds were found to decrease liver abscess formation at 10 mg/kg ip with little or no effect on normal liver mass. With P. falciparum, 35 compounds had IC50 values 50 values around 1 μM. Five compounds were again selected for in vivo investigation in a Plasmodium berghei ANKA BALB/c mouse suppressive test. The most active compound, a C9 n-alkyl side chain containing bisphosphonate, caused an 80% reduction in parasitemia with no overt toxicity. Taken together, these results show that bisphosphonates appear to be useful lead compounds for the development of novel antiamebic and antimalarial drugs.